1,030
Views
2
CrossRef citations to date
0
Altmetric
Articles

A comparative histopathological and immunohistochemical study of Survivin and Ki-67 proteins in glial tumours

, , , , , & show all
Pages 504-509 | Received 30 Sep 2018, Accepted 05 Mar 2019, Published online: 03 Apr 2019

References

  • Alifieris C, Trafalis DT. Glioblastoma multiforme: pathogenesis and treatment. Pharmacol Ther. 2015;152:63–82.
  • Gao Y, Li L, Song L. Expression of p16 and Survivin in gliomas and their correlation with cell proliferation. Oncol Lett. 2015;10:301–306.
  • Nieto-Sampedro M, Valle-Argos B, Gómez-Nicola D, et al. Inhibitors of glioma growth that reveal the tumour to the Immune System. Clin Med Insights Oncol. 2011;5:265–314.
  • Li J, Han Y, Zhou D, et al. Downregulation of survivin gene expression affects ionizing radiation resistance of human T98 glioma cells. Cell Mol Neurobiol. 2018;38:861–868.
  • Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580–584.
  • Bae IS, Kim CH, Kim JM, et al. Correlation of survivin and B-cell lymphoma 2 expression with pathological malignancy and anti-apoptotic properties of glial cell tumours. Biomedical Reports. 2017;6:396–400.
  • Chandele A, Prasad V, Jagtap JC, et al. Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia. 2004;6:29–40.
  • Zhang F, Chu J, Wang F. Expression and clinical significance of cyclooxygenase 2 and survivin in human gliomas. Oncol Lett. 2017;14:1303–1308.
  • Gazouli M, Tzanakis N, Rallis G, et al. Survivin -31G/C promoter polymorphism and sporadic colorectal cancer . Int J Colorectal Dis. 2009;24:145–150.
  • Kim HR, Lee JJ, Lee J-I, et al. Malignant glioma with neuronal marker expression: a clinicopathological study of 18 cases. J Korean Neurosurg Soc. 2015;59:44–51.
  • Prayson RA. The utility of MIB-1/Ki-67 immunostaining in the evaluation of central nervous system neoplasms. Adv Anat Pathol. 2005;12:144–148.
  • Habberstad AH, Gulati S, Torp SH. Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIα in human anaplastic astrocytomas-an immunohistochemical study. Diagnostic Pathol. 2011;6:1–8.
  • Skjulsvik AJ, Mørk JN, Torp MO, et al. Ki-67/MIB-1 immunostaining in a cohort of human gliomas. Int J Clin Exp Pathol. 2014;7:8905–8910.
  • Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther.. 2006;5:1087–1098.
  • Shirai K, Suzuki Y, Oka K, et al. Nuclear survivin expression predicts poorer prognosis in glioblastoma. J Neurooncol. 2009;91:353–358.
  • Sasaki T, Lopes BM, Hankins GR, et al. Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system. Acta Neuropathol. 2002;104:105–109.
  • Saito T, Arifin MT, Hama S, et al. Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker. J Neurooncol. 2007;82:193–198.
  • Xie D, Zeng Y, Wang H, et al. Expression of cytoplasmic and nuclear survivin in primary and secondary human glioblastoma. Br J Cancer.. 2006;94:108–114.
  • Uematsu M, Ohsawa I, Aokage T, et al. Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. J Neurooncol. 2005;72:231–238.
  • Song Z, Pan Y, Ling G, et al. Escape of U251 glioma cells from temozolomide-induced senescence was modulated by CDK1/survivin signalling. Am J Transl Res. 2017;9:2163–2180.
  • Conde M, Michen S, Wiedemuth R, et al. Chromosomal instability induced by increased BIRC5/Survivin levels affects tumorigenicity of glioma cells. BMC Cancer. 2017[Cited Dec 31 2018].17:889.
  • Wang X, Huang L, Xu Y, et al. Association between survivin − 31G > C promoter polymorphism and cancer risk: a meta-analysis. Eur J Hum Genet.. 2012;20:790–795.
  • Xu Y, Fang F, Ludewig G, et al. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol. 2004;23:527–537.
  • Jang JS, Kim KM, Kang KH, et al. Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer. 2008;60:31–39.
  • Budak M, Yildiz M. Epigenetic modifications and potential treatment approaches in lung cancers. In: Costa Torres AF, editor. Lung cancer-strategies for diagnosis and treatment. IntechOpen; 2018; p. 115–135.
  • Yalcin O, Budak M. Un-methylation of the survivin gene has no effect on immunohistochemical expression of survivin protein in lung cancer patients with squamous cell carcinoma. Bratislavske Lekarske Listy. 2017;118:160–163.